Cipla Ltd (CIPLA) is currently trading at 1,330.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs). In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid. The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability. Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products. Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.

Over the past 52 weeks, Cipla Ltd has traded between a low of ₹1,283.00 and a high of ₹1,672.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Cipla Ltd has a market capitalization of approximately 1,07,499.45. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Cipla Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.61 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Cipla Ltd (CIPLA) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 1,07,499.45 Cr, Cipla Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Cipla Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Cipla Ltd is 22.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Cipla Ltd pays dividends with a current dividend yield of 1.20%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with Cipla Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.